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Abstract 
Alzheimer’s disease (AD) is a late-onset disease that has proved difficult to model. Microglia are implicated in 
AD, but reports vary on precisely when and how in the sequence of pathological changes they become in-
volved. Here, post-mortem human tissue from two differentially affected regions of the AD brain and from 
non-demented individuals with a high load of AD-type pathology (high pathology controls) was used to model 
the disease time course in order to determine how microglial activation relates temporally to the deposition of 
hallmark amyloid-β (Aβ) and hyperphosphorylated microtubule associated protein tau pathology. Immunofluo-
rescence against the pan-microglial marker, ionised calcium-binding adapter molecule 1 (IBA1), Aβ and tau, 
was performed in the primary motor cortex (PMC), a region relatively spared of AD pathological changes, and 
compared to the severely affected inferior temporal cortex (ITC) in the same cases. Unlike the ITC, the PMC in 
the AD cases was spared of any degenerative changes in cortical thickness and the density of Betz cells and 
total neurons. The clustering of activated microglia was greatest in the PMC of AD cases and high pathology 
controls compared to the ITC. This suggests microglial activation is most prominent in the early phases of AD 
pathophysiology. Nascent tau inclusions were found in neuritic plaques in the PMC but were more numerous in 
the ITC of the same case. This shows that tau positive neuritic plaques begin early in AD which is likely of path-
ogenic importance, however major tau deposition follows the accumulation of Aβ and clustering of activated 
microglia. Importantly, findings presented here demonstrate that different states of microglial activation, cor-
responding to regional accumulations of Aβ and tau, are present simultaneously in the same individual; an im-
portant factor for consideration if targeting these cells for therapeutic intervention. 
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Alzheimer’s disease (AD) is neuropathological-
ly characterised by inclusions of microtubule-
associated protein tau (tau) and extracellular de-
posits of β-amyloid (Aβ). Intraneuronal tau pathol-
ogy includes neurofibrillary tangles (NFTs) in the 
cell soma and neuropil threads (NTs), which occur 
mostly in the dendritic compartment, but also in 
the axonal domain though to a lesser extent (1, 2). 
NFTs and NTs are both comprised of paired helical 
filaments and straight filaments of polymerised 
hyperphosphorylated tau protein (3, 4). The extent 
of tau pathology follows a predictable spatiotem-
poral progression through functionally integrated 
brain regions (5, 6) and there is an extensive body 
of literature that demonstrates an inverse correla-
tion between the accumulation of NFTs and cogni-
tive status (7) such that the spread and regional 
level of NFTs reflects the severity of dementia with 
time (8). 
Contrastingly, Aβ plaques follow a seemingly 
more haphazard regional pattern of accumulation 
throughout the neocortex, indeed plateauing rela-
tively early in the disease time course (9, 10), and 
therefore correlate poorly with disease status until 
substantial argyrophilic neuritic tau pathology is 
also present (5, 7, 11). Whilst Aβ load may be an 
unreliable indicator of disease severity, it is gener-
ally accepted that the extent of its spread, in com-
bination with tau pathology, is useful for staging 
purposes (9). Aβ plaques can be classified with 
immunostaining into at least three morphologically 
distinct categories: diffuse, fibrillar, or dense-cored. 
Diffuse plaques have long been proposed to be a 
structural precursor of other plaque forms, but 
whether these categories represent separate enti-
ties with independent mechanisms of development 
or are temporally linked is still unclear. Neuritic 
plaques (NPs) are those Aβ plaques that also fea-
ture dystrophic neurites (DNs) with silver staining. 
DNs can occur in all these morphological subtypes 
of Aβ plaques, though more commonly in dense-
cored and fibrillar plaques than morphologically 
diffuse plaques (12). Most DNs are tau-positive and 
morphologically similar to NTs which are elongated 
in shape, but may also be globular, and possibly 
represent swollen presynaptic (axonal) terminals 
(13). NPs that retain sparse DNs but show minimal 
Aβ staining have previously been described and 
were termed ‘remnant plaques’ which were pro-
posed to result from glial phagocytosis of insoluble 
Aβ (14). 
There remains significant debate as to the se-
quence of the neuropathological changes that pre-
cede the onset of AD symptomatology. The amyloid 
cascade hypothesis posits Aβ, and in particular the 
soluble, oligomeric, non-fibrillar fraction, as the 
initiating factor (15-20). A competing view is of-
fered by others who contend that the sequence of 
pathological events begins with neurofibrillary pa-
thology (21, 22) which precedes the formation of 
insoluble Aβ pathology (23). Indeed, there is evi-
dence that tau pathology occurs prior to Aβ pa-
thology as it is more common in the brains of non-
demented individuals (21) but this might represent 
a non-AD scenario described as primary age-related 
tauopathy (PART) (24). Notwithstanding the order 
of events, both hypotheses suggest that an activat-
ed glial response is an integral component of the 
pathogenesis of AD. 
The study of microglia morphology in post-
mortem human brain tissue presents a simple 
method with which to gauge the involvement of 
microglia in instances of changed physiological 
conditions or to the development of a disease. Mi-
croglia with a ramified morphology, characterised 
by thin, evenly distributed, highly branched pro-
cesses with a small, spherical soma, represent the 
healthy cell population (25-27). Activated microglia 
are characterised by reduced morphological com-
plexity including hypertrophy of the soma and pro-
cesses and may also display the formation of distal 
phagosomes (23, 25, 28). Dystrophic microglia dis-
play features consistent with cellular senescence 
(29), including a loss of processes, tortuosity of 
remaining processes, and discontinuous IBA1-
immunolabelling (30-32). Lastly, clusters of activat-
ed microglia in AD have been noted previously in 
post-mortem human brain tissue and represent the 
direct interaction between microglia and Aβ and 
tau pathology (10, 32, 33). 
By investigating brain regions differentially af-
fected by AD-type pathology in non-demented and 
demented individuals it may be possible to model 
the sequence of pathological changes in the dis-
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ease, in particular the activated microglial re-
sponse. Previously we demonstrated an increased 
density of activated microglia in the inferior tem-
poral cortex (ITC) of non-demented controls with 
similar levels of AD-type pathology (‘high pathology 
controls’ – HPCs) as clinically and neuropathologi-
cally-confirmed AD cases (26). This suggested that 
the microglial response occurs in the preclinical 
phases of AD but we wished to confirm this finding 
in a belatedly affected region of the AD brain, the 
primary motor cortex (PMC), compared to an earli-
er and more severely affected region, the ITC, of 
the same cases. Further, we wished to determine 
the sequence of Aβ, tau, and microglia pathological 
changes that occur in the cortex. The findings here 
demonstrate that nascent NTs and DNs in the PMC 
begin early in the pathogenesis of AD, but follow 
the clustering of activated microglia. By contrast, 
looking at the severely affected ITC in the same 
cases, findings suggest that microglial clustering at 
plaques dissipates once tau and Aβ pathology is 
long established and there is also a substantial loss 
of IBA1-immunoreactivity (26, 34). Although an 
early toxic microglial gain of function cannot be 
ruled out, these findings appear most consistent 
with a scenario where microglial activation is neu-
roprotective early in the pathogenesis of AD. We 
suggest that this is followed by a gradual exhaus-
tion of microglial function that contributes to cog-
nitive deterioration in the AD brain. 
 
Table 1. Cohort characteristics. 
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This study was approved by the University of 
Sydney’s Human Research Ethics Committee 
(HREC#2015/477). All tissue samples for this study, 
as well as demographic and clinical information, 
were supplied by the New South Wales Brain Tissue 
Resource Centre (NSWBTRC) and the Sydney Brain 
Bank (SBB), collectively the New South Wales Brain 
Banks (NSWBB), following approval from their Sci-
entific Advisory Committee. Methods for case as-
certainment and tissue preparation by NSWBB 
have been previously published (35). The demo-
graphic and clinicopathological characteristics of 
the cohort (Table 1) and data from the ITC have 
been previously published (26). 
Immunofluorescence 
Immunofluorescence staining procedures 
were performed on free-floating 45 μm fixed sec-
tions derived from the caudal aspect of the super-
omedial area of the PMC of controls (n = 10), HPCs 
(n = 5), and pathologically confirmed AD cases (n = 
8) as previously described (26). Double-labelled 
sections using antibodies against Aβ, total tau 
(TTau), and the pan-microglial marker ionised calci-
um-binding adapter molecule 1 (IBA1), were used 
for the quantification of Aβ and tau loads and mi-
croglial morphological subtypes. 
For Aβ and IBA1 quantification, heat-induced 
epitope retrieval was performed using a sodium 
citrate solution (pH 8.5) at 60°C overnight, followed 
by a 12-minute formic acid (90%) incubation at 
room temperature. Blocking was performed in 10% 
normal goat serum (Gibco #16210072), and prima-
ry (mouse Aβ, 1:1000, BioLegend 803002; rabbit 
IBA1, 1:1000, Wako 019-19741) and secondary 
(1:200; Thermo Scientific: Alexa Fluor (AF) 488 goat 
anti-mouse, #A11001; AF 568 goat anti-rabbit, 
#A11011) antibody incubations were performed at 
4°C with gentle agitation. Nuclear counterstaining 
was performed in the last 40 minutes of the sec-
ondary antibody incubation by the addition of 
Hoechst 33342 dye (1 µg/mL; Thermo Scientific 
62249). Sections were mounted using Prolong Dia-
mond Antifade (Invitrogen P36961). Double-
immunolabelling of TTau (rabbit; 1:500; Dako 
K9JA/A0024) and IBA1 (mouse; 1:50; Millipore 
MABN92) was carried out as previously described 
(34). TTau immunostaining of NFTs, NTs, and DNs 
has previously been demonstrated to give compa-
rable immunostaining to standard phosphotau 
antibodies (12E8 and AT8) (36). Briefly, heat-
retrieval was performed with sodium citrate (pH 
6.0) for 10 minutes at 100°C, before permeabilising, 
blocking with BSA, and incubating in primary anti-
bodies for three hours at room temperature or 
overnight at 4°C, and finally incubating in second-
ary antibodies (1:200; Invitrogen: AF555 goat anti-
mouse, A214424; AF647 goat anti-rabbit, A21244). 
Hoechst 33342 was added to counterstain nuclei 
and sections were mounted in ProLong Gold Anti-
fade. 
Image acquisition and analysis 
Aβ and IBA1 double-labelled sections were 
imaged using a Zeiss LSM 800 confocal microscope 
using the ‘tile scan’ function at the Advanced Mi-
croscopy Facility, Bosch Institute, The University of 
Sydney. A previously validated modified disector 
sampling approach that utilises one section per 
individual was used here for the analysis of the Aβ 
and IBA1 immunostained sections (37). Briefly, a 
total of three cortical strips per section from areas 
where the pial surface and the grey-white bounda-
ry were strictly in parallel were acquired for the 
quantification of microglia, Aβ plaques and Aβ-
positive pixels. These cortical strips were con-
structed of serial images 500 μm in width, 6 μm in 
z-depth with three z-slices (z-step = 3 μm), span-
ning all of the cortical laminae of the PMC using a 
20×/0.8 numerical aperture (NA) objective. Clusters 
of microglia and individual microglia, which were 
categorised as having either a ramified, activated, 
or dystrophic morphology as previously described 
(26), were enumerated in image analysis software 
(Fiji; NIH). The terminology used to describe the 
different populations of morphologically diverse 
populations of microglia was informed by previous 
investigations (25, 28, 30). Microglia with thin, 
highly branched processes, and a spherical nucleus 
were categorised as ‘Ramified’. ‘Activated’ micro-
glia (previously termed ‘deramified’ (34)) included 
those cells that displayed hypertrophy of the soma 
or processes with retraction of secondary or ter-
tiary processes. ‘Dystrophic microglia’ were identi-
fied on the basis of a loss of processes with the 
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remaining processes displaying significant tortuosi-
ties or discontinuous IBA1-immunolabelling with or 
without blebbing or punctate IBA1-labelling (previ-
ously dystrophic microglia were subcategorised as 
either ‘punctate’ or ‘discontinuous’ to reflect these 
observations (34)). A ‘Cluster of microglia’ was 
counted if three or more soma occurred within, or 
were touching the margins of, a 20 μm2 virtual grat-
icule subregion. Larger clusters were counted as 
one cluster if the graticule subregion could be 
moved and still incorporate at least three somata. 
Clusters were counted whilst visualising only the 
568 nm (IBA1-positive) channel to distinguish these 
from individual microglia and to minimise potential 
false-positive counts in the presence of either Aβ- 
or TTau-immunostaining. The total number of mi-
croglia counted per section averaged 519 with a 
coefficient of error (CE) of ≤0.2 for all counts of 
morphological subtypes, with the exception of mi-
croglial clusters (CE ≤0.3) which were relatively rare 
and displayed significant variance between cases. 
Quantification of TTau was carried out using 
an Olympus VS120 slide scanner at the Sydney Mi-
croscopy and Microanalysis, Brain and Mind Cen-
tre, The University of Sydney. Whole section DIC 
and fluorescence overviews of a single section from 
each case were generated using a 10× objective 
and were used to systematically map out four rep-
resentative 500 μm2 regions of interest (= 1mm2 
per section) within the mid-cortical laminae (III-V) 
for manual counts of NFTs and for the quantifica-
tion of TTau-positive pixels. Individual images were 
captured using a 40×/0.9 NA objective and were 
comprised of seven z-slices with a depth of 6 μm (z-
step = 1 μm). Image analysis was performed in Fiji 
using manually thresholded images. Positive pixel 
counts were generated for Aβ and TTau staining 
and expressed as a percentage of total pixels (% Aβ 
and % TTau respectively). High resolution imaging 
of all immunolabelled sections were carried out 
using a Nikon A1R or Zeiss LSM 710 confocal micro-
scope (Sydney Microscopy and Microanalysis, 
Charles Perkins Centre and Brain and Mind Centre, 
The University of Sydney). Features were imaged 
with either a 40×/0.95 NA or 100×/1.4 NA objective 
and shown as maximum intensity projections. 
Nissl staining 
Nissl stains of free-floating 45 μm thick forma-
lin-fixed sections were performed for the meas-
urement of cortical thickness and neuronal counts. 
Sections were incubated in 0.1% cresyl violet ace-
tate (0.02% glacial acetic acid; added immediately 
before use) for 15 minutes at 60°C. Differentiation 
was achieved by sequentially washing sections for 
three minutes in 70% and 95% ethanol. The final 
level of staining was adjusted by briefly dipping 
sections in 100% ethanol and confirmed by light 
microscopy before clearing in xylene for ten 
minutes and mounting in DPX. Cortical thickness 
measurements and neuronal counts were per-
formed on three cortical strips from one section 
per individual using an eyepiece graticule on an 
Olympus BX50 microscope using a 20×/0.75 NA 
objective. A height measure of 45 μm was used in 
determining density estimates to eliminate artefac-
tual tissue shrinkage during staining; with the mi-
crotome accuracy to cut precise sections having 
been previously validated (37). CEs using the modi-
fied disector technique outlined above were <0.1 
for cortical thickness and <0.15 for the density of 
Betz cells and total neurons. 
Statistical analyses 
The normality of data was tested using the 
Shapiro-Wilk test. Equality of variances was tested 
using Brown-Forsythe test. Group differences were 
investigated by either Welch’s analysis of variance 
or Kruskal-Wallis test for non-Gaussian distribu-
tions, with either Games-Howell or Dunn’s test, 
respectively, for pairwise comparisons. Regional 
differences to the previously reported ITC (26) 
were investigated by either Welch’s T test or Wil-
coxon rank-sum test for non-Gaussian distributions. 
The Pearson correlation coefficient (r) and coeffi-
cient of determination (r2), or Spearman rho (ρ) for 
non-Gaussian distributions, were calculated for 
univariate correlations to investigate relationships 
between AD-type pathology, microglial morpholo-
gies, and APOE ε4 status. Stepwise regression 
models which included age, sex, brain pH, post-
mortem interval, and fixation period were per-
formed to exclude effects of potential confounders. 
A p-value <0.05 was considered statistically signifi-
cant. All statistical analyses were performed using 
JMP Pro 14 (SAS Institute Inc). Graphs were pro-
duced using Microsoft Excel. 
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The Alzheimer’s disease primary motor cortex 
exhibits mild tau and β-amyloid deposition but 
no evidence of neurodegeneration 
This study involved 23 autopsy cases that had 
previously been clinicopathologically characterised 
as ‘probable AD’ or controls based on ABC score 
and clinical dementia rating (Table 1) (39). AD cases 
(n=8) included individuals with an intermediate–
high likelihood of AD dementia following routine 
neuropathological diagnostic testing (38) and who 
presented with typical AD dementia prior to death. 
‘High pathology controls’ (HPC) (n=5) were grouped 
as such on the basis of no cognitive impairment but 
satisfied a diagnosis of intermediate AD likelihood 
on post-mortem examination. Controls (n=10) in-
cluded individuals with a range of ABC scores (A0–
3; B0–2; C0–3), though only satisfying a ‘Not’ or 
‘Low’ outcome after diagnostic testing. 
There was no cortical atrophy (Fig. 1a) or neu-
ronal loss (Fig. 1b), including the prominent layer 
Vb Betz cells (Fig. 1c), in the PMC of AD cases or 
HPCs compared with controls. Following a positive 
pixel analysis, grey matter Aβ areal fraction (% Aβ) 
was higher in the PMC of AD cases compared to 
controls (p = 0.0005), but not HPCs (p = 0.07). The 
density of total Aβ plaques, fibrillar, and dense-
cored plaques was also significantly higher in AD 
cases compared to controls (Totalp = 0.003; Fibrillarp = 
0.002; Dense-coredp = 0.004) but not HPCs (Totalp = 0.1; 
Fibrillarp = 0.06; Dense-coredp = 0.2). Total tau areal frac-
tion (% TTau) and the density of NFTs was higher in 
the PMC of AD cases compared to controls (%TTaup = 
0.001; NFTp = 0.001) and HPCs (%TTaup = 0.007; NFTp = 
0.01) (Table 2). 
Amongst the AD cases, the PMC had signifi-
cantly reduced % Aβ (p = 0.006), total Aβ plaques 
(0.001), and fibrillar plaques (p = 0.0002), but not 
dense-cored plaques (p = 0.2) compared to the ITC. 
The % TTau (p = 0.02) and the density of NFTs (p = 
0.02) were also significantly reduced in the PMC 
compared to the ITC of AD cases. Amongst controls 
the % TTau was significantly reduced in the PMC 
compared to the ITC (p = 0.04). There were no oth-
er regional differences in terms of pathological load 
in controls, including amongst HPCs (Table 3). 
In the ITC, all of the control, HPC, and AD cas-
es had neuritic tau pathology at varied levels. Aβ 
pathology in the ITC occurred in 4/10 controls, and 
all HPCs and AD cases. The clustering of activated 
microglia in the ITC was apparent in 6/10 controls 
(including three with only tau pathology), and all of 
the HPCs and AD cases except one (M12) (ITC case 
data is shown in Fig. 1d). In the PMC, neuritic tau 
pathology was present in 7/10 controls, 4/5 HPCs, 
and all AD cases, while Aβ deposition in the PMC 
occurred in 6/10 controls, 4/5 HPCs, and all AD 
cases. Microglial clustering in the PMC was ob-
served in 5/10 controls, and all of the HPCs and AD 
cases, with the exception of one case (M12) (PMC 
case data is shown in Fig. 1e). In controls, the % 
TTau correlated with age in the PMC (r2 = 0.44, p = 
0.04) but not in the ITC, which was near significant 
(r2 = 0.39, p = 0.05). 
Table 2. Summary of neuronal and neuropathological data of the primary motor cortexa 
 
aMean ± standard deviation. 
bANOVA results; see text for p-values of pairwise comparisons. 
cInclusive of Betz cells. 
dDensity of Betz cells in layer V. 
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Figure 1 Characteristics of the PMC and regional neuropathological comparisons. a–c The PMC is spared of AD-related neurodegenera-
tive changes as measured by cortical thickness (a), total neuronal density (b), and the density of layer Vb Betz cells (inset demonstrates 
a pyramidal Betz cell with multiple asymmetrically distributed perisomatic neurites, a prominent nucleolus, and a dark dense deposit of 
cytoplasmic lipofuscin) (c). d–e A cohort wide comparison of the percentage of Aβ and TTau immunolabelling and microglial clustering 
in the ITC (d) and PMC (e) demonstrates age-related tau build-up in a majority of control brains in both regions and an early build-up of 
Aβ in HPCs (that were scored as A2-3, B2, C0-3 on diagnostic slides) with a concomitant microglial clustering response that is more 
prevalent in the PMC compared to the ITC and which appears to dissipate with severe AD pathology in the ITC. Scale bar = 50 μm (c)  
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Table 3. Regional neuropathological comparisonsa. 
 




Clusters of activated microglia are more com-
monly found in the PMC than the ITC of HPCs 
and AD cases 
The density of individual activated (Fig. 2a–e), 
ramified (Fig. 2f), dystrophic (Fig. 2g–h), or total 
microglia did not differ between any of the three 
groups in the PMC (Table 4). Microglial clusters 
(Fig. 2i–j), although a small proportion of total mi-
croglia, were significantly more common in HPCs 
(Fig. 2k) and AD (Fig. 2l) cases compared to controls 
in the PMC (HPCp = 0.01; ADp = 0.04). 
Clusters in the PMC were also higher than in 
the ITC of HPCs (p = 0.02) and AD cases (p = 0.03) 
(Fig. 3a), whilst the density of total (p = 0.04) and 
ramified microglia (p = 0.002) were reduced in the 
ITC compared to the PMC of AD cases. Immunoflu-
orescent double-labelling for Aβ and IBA1 in the 
PMC showed that the clusters of activated micro-
glia, occurred preferentially within the boundaries 
of fibrillar Aβ plaques, with a significant correlation 
in a combined analysis of control and AD brains 
(Spearman ρ = 0.54, p = 0.006; Fig. 3a). The per-
centage of Aβ plaques associated with a cluster of 
activated microglia in the PMC ranged from a mean 
of 41% in controls and 43% in AD cases to 60% in 
HPCs, with one control (M15), two HPCs (M14 and 
M18), and one AD case (M13) having a higher den-
sity of microglial clusters than Aβ plaques. 
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Figure 2 Response of microglia to AD pathology. a–e A spectrum of microglial activation can be identified by a series of morphological 
changes including an enrichment of IBA1 labelling of the soma and primary processes (a), hypertrophy of the primary processes (b), 
retraction of tertiary processes ± the formation of morphological features consistent with phagosomes (arrow heads) (c), further retrac-
tion of secondary processes (d), until amoeboid in shape (e). f–h Healthy ramified microglia have a small, spherical soma and thin, even-
ly distributed processes (f), contrasting with dystrophic microglia that have either deramified and tortuous processes (g) or pseudo-
fragmentation of processes when marked with IBA1 (h). i–j Microglia that form a cluster within the boundary of an Aβ plaque may be 
either dystrophic or have reached a phase of early (i) or late/amoeboid (j) activation. k–l Mosaics of IBA1 staining demonstrating the 
size and distribution of microglial clusters (arrows), defined as three or more somata occurring within, or touch the boundaries of, a 20 
μm2 virtual graticule subregion, in the PMC of an HPC (k; M23) and AD case (l; M13). Scale bar in j = 40 μm (a–j); in l = 100 μm (k–l) 
 
Figure 3 Characteristics of microglial clustering in the PMC. a The density of microglial clusters was significantly greater in the PMC of 
HPCs and AD cases compared to controls. b Microglial clusters were more frequently associated with fibrillar neuritic plaques in a com-
bined group analysis; Spearman ρ = 0.54, p = 0.006. †Significantly reduced compared to PMC of HPCs; ‡Significantly reduced compared 
to PMC of AD cases. *†‡p<0.05.  
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Table 4. Quantification of the morphological subtypes of microglia in the primary motor cortexa 
 
aCells/mm2; mean ± standard deviation. 
bANOVA results; see text for p-values of pairwise comparisons of microglial clusters. 
 
A graded extent of neuritic tau pathology and 
clustering of microglia occurs within nascent Aβ 
plaques, with the persistence of dystrophic neu-
rites and the loss of IBA1-immunoreactivity and 
Aβ-immunoreactivity occurring in established 
neuritic plaques 
All of the Aβ plaques examined in the ITC, and 
a majority in the PMC, contained DNs. However, 
the extent of the accumulated neuritic tau patholo-
gy within each plaque was lower in the PMC (Fig. 
4a) than the ITC of the same case (Fig. 4b). Both Aβ 
deposits and globular DNs were seen perivascularly 
(Fig. 4c), consistent with previous observations 
(39). The density of DNs was greatest in the ITC of 
AD cases (Fig. 4c), which also had the highest densi-
ty of remnant plaques characterised by accumula-
tions of DNs associated with weak or absent Aβ-
immunoreactivity (Fig. 4d). In the ITC a diffuse lat-
tice of elongated NTs occurred throughout the neu-
ropil and independently of Aβ plaques (Fig. 4e). 
DNs appeared radially projecting from Aβ plaques 
(Fig. 4e) and showed either elongated or globular 
morphology (Fig. 5a). Hoechst dye marked cell nu-
clei around the periphery of Aβ plaques and also 
partly stained the fibrillar deposits of Aβ (Fig. 5a). 
Hoechst has previously been reported to stain Aβ 
plaques in transgenic mice (40). Immunofluores-
cent double-labelling showed no colocalisation of 
Aβ and TTau (Fig. 5b). 
Microglia cell processes exhibiting evidence of 
phagocytic activity are interspersed around the 
periphery and core of Aβ plaques 
Microglia that occurred in proximity to diffuse, 
fibrillar, and cored plaques commonly displayed 
structures morphologically consistent with phago-
somes on distal processes with enriched IBA1 im-
munolabelling that closely associated with the Aβ 
element in the periphery and core of plaques (Fig. 
6a; Fig. 7a). As previously reported for the ITC, su-
perior frontal gyrus, and primary visual cortex, the 
overall density of dystrophic microglia was inverse-
ly correlated with brain pH in the PMC (r2 = 0.3, p = 
0.01) (26). However, it was also noted that individ-
ual plaques with dense DNs, that were associated 
with weak or absent Aβ staining which were more 
abundant in the ITC, were associated with dys-
trophic microglia (Fig. 6b) rather than a cluster of 
activated microglia which more commonly oc-
curred where the extent of DNs was not yet fully 
developed (Fig. 6c–d). Confocal views showed co-
localisation of microglial cell processes with Aβ in 
AD (Fig. 7a–b), but no co-localisation with tau pa-
thology (Fig. 7c–d). 
Discussion 
AD is a uniquely human disease with a long 
prodrome and has proved difficult to model. The 
combination of using different regions of post-
mortem brain tissue from individuals with or with-
out dementia and with variable amounts of AD-
type pathology may allow the pathological se-
quence of events to be elucidated. For example, 
the level of disease severity could be ordered from 
lowest to highest as follows: PMC-controls < ITC-
controls < PMC-HPC < ITC-HPC < PMC-AD < ITC-AD. 
In particular, regions such as the ITC in HPCs and 
the PMC in AD cases could harbour the pre-
symptomatic targets required to therapeutically 
delay or prevent AD. Prior to using this model to 
understand the role of microglia in AD, a quantita-
tive neuropathological analysis of the PMC was 
carried out to ensure that it met expectations for 
being a relatively unaffected region of the AD brain. 
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Figure 4 Immunofluorescent double-labelling for Aβ and TTau. a–c The majority of Aβ plaques examined here were associated tau-
positive dystrophic neurites, with a clear gradation visible between the PMC (a) and ITC (b) in controls (M01 pictured in a and b) and AD 
cases (ITC of M09 pictured in c). AD cases had the most extensive build-up of DNs in fibrillar and dense-cored plaques, as well as peri-
vascular (capillary) Aβ deposits (c). d Remnant plaques (arrows) are characterised by absent or weak Aβ staining and dense accumula-
tions of tau pathology and were much more common in the ITC than the PMC (also seen in b). e Severely affected regions of the AD 
brain, such as the ITC, showed a diffuse network of elongated NTs throughout the parenchyma as well radially projecting DNs. Scale bar 
= 20 μm (a–c), 60 μm (d), 40 μm (e)  
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Figure 5 High power image of an Aβ plaque in AD. a Image panel showing a fibrillar neuritic plaque in an AD case (M03) with globular 
and threadlike DNs distributed throughout the plaque, which is also surrounded by a network of NTs (dotted box in merged image 
demonstrates ROI shown in b). Hoechst staining labelled cell nuclei around the periphery of the plaque as well as the fibrillar Aβ com-
ponent inside the plaque. b Colocalisation study showed no coincidence Aβ and TTau staining in any of the sections examined here 
(dotted line represents a 6.5 μm length along which pixel intensities have been compared in this exemplar ROI). Scale bar = 20 μm (a)  
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Figure 6 Responses of microglia to AD neuropathology. a The ITC of a control case (M01) demonstrating activated microglia with mor-
phological features consistent with the formation of phagosomes (arrows) responding to peripheral and core elements of an Aβ plaque. 
b In the ITC of AD cases (M17 pictured), dystrophic microglia were more commonly associated with plaques that contained dense accu-
mulations of dystrophic neurites, however the overall density of dystrophic microglia was inversely correlated with brain pH and not 
with AD. c–d Conversely, plaques with a lower density of dystrophic neurites were more commonly associated with a cluster of activat-
ed microglia (M01 pictured) in both the PMC (c) and ITC (d). Scale bar = 20 μm (a–d)  
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Figure 7 Exemplars from an investigation into the potential internalisation of Aβ and tau pathology by microglia. a Activated microglia in 
an Aβ plaque in the ITC of a control case with morphological features consistent with the formation of phagosomes (arrows) (M01; 
dotted box represents region of interest in b). b Coincidence of Aβ and IBA1 pixel intensities along a 7.8 μm length (dotted line) suggests 
potential internalisation of Aβ by microglia. c Activated microglia in close proximity to tau-positive DNs in the ITC of an AD case (M17; 
dotted box represents region of interest in d). d There was no evidence of the internalisation of tau pathology by microglia in any of the 
sections investigated here; exemplar shows Aβ and TTau staining intensities over a 7.2 μm length (dotted line). Scale bar 20 μm (a, c) 
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As expected, the PMC of AD cases had a signif-
icantly higher % Aβ, Aβ plaque count, % TTau, and 
NFT density compared controls. There were no 
NFTs observed in the PMC of controls and HPCs, 
which also had very similar levels of % TTau (which 
correlated with increasing age), but differed in their 
level of % Aβ. HPCs were defined according to 
standard neuropathological diagnostic criteria – 
having an intermediate ABC score (38). Incidentally, 
HPCs and AD cases (intermediate–high ABC scores) 
were similar in their Aβ load but differed in their 
tau levels in both regions. In contrast to the prima-
ry visual cortex previously investigated (26), the 
PMC in AD did have significantly reduced levels of 
Aβ and overall tau pathology, including NFTs as 
well evidenced elsewhere (41-46), compared to the 
ITC of the same cases. Overall there was no evi-
dence of neurodegeneration in the PMC of AD cas-
es, unlike the ITC, with cortical thickness, number 
of total neurons, and giant layer Vb pyramidal Betz 
cells remaining unchanged as expected (47, 48). 
Examination of the microglial morphologies in 
the PMC using the previously validated modified 
disector sampling approach across all cortical lami-
nae yielded no significant differences between 
controls, HPCs, and AD cases. However, group dif-
ferences could be seen locally around AD-type pa-
thology within the cortex with an increase in clus-
tering of activated microglia in the PMC of HPCs 
compared to controls, and in the PMC compared to 
the ITC of AD cases. Moreover, a higher percentage 
of plaques contained clusters of microglia in HPCs 
than in AD cases and also a portion of microglia 
clusters that were not spatially associated with Aβ. 
The presence of a strong microglial clustering re-
sponse in the PMC of AD cases and in the HPCs 
aligns with PET imaging studies demonstrating ear-
ly activation of microglia in preclinical AD cases 
(49). Although the presence of clusters unrelated to 
Aβ pathology may be a non-specific observation, it 
is interesting to note that a previous animal study 
using a 5×FAD model also reported the presence of 
microgliosis prior to the formation of insoluble Aβ 
plaques (50), with another mouse model also indi-
cating microglial activation in relation to synaptic 
dysfunction prior to Aβ deposition (51). 
Here it is suggested that clusters of activated 
microglia in the PMC represent a neuroprotective 
response correlating with the deposition of Aβ. We 
have demonstrated clusters of activated microglia 
that display phagocytic capabilities in the mildly 
affected PMC before the development of extensive 
tau pathology. It is conceivable that once the phag-
ocytic potential of microglia is overwhelmed, a 
transition to a more neurotoxic proinflammatory 
phenotype occurs and that this represents a pivotal 
moment preceding tau-related neurofibrillary de-
generation. Studies in mouse models of Aβ overex-
pression suggest proinflammatory microglia, which 
may be induced by the binding of oligomeric and 
fibrillar Aβ species to NLR Family Pyrin Domain 
Containing 3, Receptor for Advanced Glycation 
Endproducts, Scavenger receptors, and Toll-like 
receptors, among others (52-58), are associated 
with poorer cognitive and survival outcomes, have 
impaired phagocytic capabilities (59), and are ca-
pable of secreting an expansive complement of 
neurotoxic compounds including reactive oxygen 
species, nitric oxide, peroxynitrite, tumour necrosis 
factor α, interleukin 1 β, and prostaglandin-E2 (60). 
However Aβ-independent mechanisms of microglia 
activation or exhaustion in human AD cannot be 
excluded and require further research considering 
the so far limited efficacy of the pharmacological 
clearance of Aβ in clinical trials (61, 62). 
Activated microglia tended to be associated 
with fibrillar NPs, and higher resolution confocal 
photomicrographs showed evidence of Aβ internal-
isation by microglia in both regions. The latter may 
explain the remnant plaques observed here (that 
contain weak or absent Aβ-immunolabelling; in 
which higher levels of Aβ were associated with 
activated microglia, but dystrophic microglia where 
Aβ-immunoreactivity was very minimal or absent, 
particularly where dystrophic neurites were exten-
sive) and described elsewhere (14) and is potential-
ly relevant to the proposed dynamic equilibrium 
between soluble Aβ oligomers and insoluble fibrils 
(63). However, it will be important to confirm the 
internalisation of Aβ by microglia with super reso-
lution techniques such as direct stochastic optical 
reconstruction microscopy (dSTORM). In contrast, 
microglia did not specifically cluster around any of 
the three forms of tau pathology, NFTs, NTs and 
DNs, nor did they appear to internalise tau in co-
localisation studies, although processes of microglia 
were coincidentally found adjacent to DNs. The 
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microglial clustering response dissipated over the 
modelled disease course with advanced stages, 
represented by the ITC of AD cases, being charac-
terised by reduced IBA1 immunoreactivity, as re-
ported elsewhere (31, 64). This suggests a process 
of microglial incapacitation in the context of in-
creased tau load, a concept which is supported by a 
growing body of literature (65, 66). From these 
results it is hypothesised that the activation of mi-
croglia coincides with cortical Aβ deposition. Neu-
ritic inclusions of tau in the cortex are evident early 
in the disease process, represented here by the 
PMC of AD cases, but mainly develop after the 
deposition Aβ and the activation of microglia. 
This sequence of pathological changes is os-
tensibly consistent with the amyloid cascade hy-
pothesis for AD pathogenesis (19) given the pres-
ence of elevated Aβ in the PMC of HPCs, however it 
should be stressed that the levels of Aβ and tau 
pathology were present at similar levels in the PMC 
of confirmed AD cases. Therefore it could be ar-
gued that insoluble Aβ and tau deposits begin 
forming concurrently in the cerebral cortex of AD 
brains. This would be consistent with those arguing 
in favour of the pathogenetic importance of tau 
deposition (22, 23, 67, 68) and the possibility that it 
in fact acts as a causative factor behind AD-related 
microglial activation (69). Certainly, animal models 
suggest that microglial activation augments tau 
pathology and specifically tau phosphorylation (70). 
This scenario would then be consistent with our 
observation that microglial activation wanes with 
increased tau deposition and with the idea that 
ageing impairs the housekeeping functions of mi-
croglia (71). Finally, even in the presence of exten-
sive tau pathology, the increased presence of rem-
nant plaques in the ITC suggests that microglia re-
tain the ability to clear Aβ peptides. 
Understanding the functional significance of 
these dynamic spatiotemporal changes in microgli-
al activity along the time course of AD pathophysi-
ology will be critical before new treatments target-
ing these cells can be imagined. Given that micro-
glia of different brain regions display different acti-
vation states simultaneously depending on the 
graded extent of AD-type pathology present, the 
implementation of either anti- or pro-inflammatory 
microglia-based therapies would presumably be 
beneficial in one brain region but detrimental in 
another. In future work the genetic characterisa-
tion of subjects investigated here may also provide 
further insight into how genotype affects individual 
susceptibility to differential microglial function, 
represented by the highly variable clustering re-
sponse of microglia in HPCs and AD cases in par-
ticular. Overall, findings from the post-mortem 
model used here suggest that the clustering of acti-
vated microglia occurs concomitantly with the for-
mation of Aβ plaques, and that tau-related neuritic 
degeneration follows these changes along with a 
loss of clustering. 
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